Armata Pharmaceuticals Revenue and Competitors

Location

$196M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Armata Pharmaceuticals's estimated annual revenue is currently $13.8M per year.(i)
  • Armata Pharmaceuticals's estimated revenue per employee is $155,000
  • Armata Pharmaceuticals's total funding is $196M.

Employee Data

  • Armata Pharmaceuticals has 89 Employees.(i)
  • Armata Pharmaceuticals grew their employee count by -7% last year.

Armata Pharmaceuticals's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
VP , OperationsReveal Email/Phone
4
VP ResearchReveal Email/Phone
5
VP, Business and Corporate DevelopmentReveal Email/Phone
6
VP, Program Management and OperationsReveal Email/Phone
7
Chief Medical OfficerReveal Email/Phone
8
Scientific DirectorReveal Email/Phone
9
Associate DirectorReveal Email/Phone
10
Sr. Director Quality ControlReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Armata Pharmaceuticals?

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. More information is available at www.armatapharma.com

keywords:N/A

$196M

Total Funding

89

Number of Employees

$13.8M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Armata Pharmaceuticals News

2022-04-20 - CBRE Brokered Sale Of Property In Marina Del Rey After Renovation

Armata Pharmaceuticals had leased the entire property starting in 2021. CBRE representatives Mike Longo,Todd Tydlaska, Sean Sullivan,...

2022-03-30 - Scrambling for Talent and More Office Space, Life Sciences ...

Stream Realty Partners represented Armata Pharmaceuticals in the lease. Tim Dwight, from Stream Realty, said, "This new facility will allow them...

2022-03-30 - Armata Pharmaceuticals Announces Closing of Second and Final ...

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of...

2021-08-12 - Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update

MARINA DEL REY, Calif., Aug. 12, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today anno ...

2021-08-02 - Armata Pharmaceuticals Announces Chief Executive Officer Transition

MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infection ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.1M93-11%$63.5M
#2
$12.7M9856%$67M
#3
$25.9M10248%N/A
#4
$17.1M114-8%N/A
#5
$18.1M12517%N/A